Bhupat Desai, MD
Neurology · Upland, CANPI 1649362633
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,423 of the $6,062 with a category attached, or 89.5%. 30 manufacturers reported payments, led by AbbVie at 36.9% of the total.
Across 294 payments — averaging $20.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Acadia Pharmaceuticals Inc$1K
- Medtronic$763
- Novartis$386
- Biogen$223
- Eisai Inc.$196
- plus $1K from 24 others
Across 10 payments — averaging $4110.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Avanir Pharmaceuticals, Inc.$12K
- Acadia Pharmaceuticals Inc$12K
- AbbVie$11K
- Biogen$6K
What the payments were for
- Travel & lodging$62610%
- Food & beverage$5,42389%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 144 | $2,238 |
| Acadia Pharmaceuticals Inc | 70 | $1,070 |
| Medtronic | 5 | $763 |
| Novartis | 24 | $386 |
| Biogen | 5 | $223 |
| Eisai Inc. | 7 | $196 |
| AstraZeneca | 3 | $160 |
| EMD Serono, Inc. | 4 | $122 |
| Pfizer | 5 | $109 |
| Johnson & Johnson | 1 | $106 |
| Bristol Myers Squibb | 4 | $94 |
| Livanova USA, Inc. | 2 | $84 |
| Abbott | 1 | $67 |
| Octapharma USA, Inc. | 1 | $51 |
| MDD US Operations, LLC | 2 | $51 |
| Penumbra, Inc. | 1 | $38 |
| Lundbeck LLC | 2 | $36 |
| Argenx US, Inc. | 1 | $34 |
| Amgen | 1 | $32 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Adamas Pharmaceuticals, Inc. | 1 | $23 |
| Amneal Pharmaceuticals LLC | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| UCB, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Zogenix Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PERCEPT PC BRAINSENSE$596
- ULTOMIRIS$129
- INVOKANA$106
- ACTIVA PC$104
- Leqembi$101
How this compares
$6,062 in reported general payments places this provider in the 70th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 43 | $1,712,515 |
| UltomirisRavulizumab-Cwvz | 12 | $957,326 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 14 | $669,466 |
| SolirisEculizumab | 14 | $644,576 |
| MayzentSiponimod | 18 | $166,831 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 17 | $166,083 |
| AptiomEslicarbazepine Acetate | 31 | $49,429 |
| NeuproRotigotine | 11 | $10,597 |
| Rasagiline Mesylate | 58 | $10,203 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 178 | $5,478 |
| Adderall XrDextroamphetamine/Amphetamine | 12 | $4,986 |
| Levetiracetam | 123 | $4,506 |
| Mycophenolate Mofetil | 27 | $3,004 |
| Primidone | 52 | $2,705 |
| Pregabalin | 76 | $2,430 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $16 | $1,712,51543 claims |
| AstraZenecaUltomiris, Soliris | $160 | $1,601,90126 claims |
| NovartisMayzent | $386 | $166,83118 claims |
| PfizerOctagam | $109 | $166,08317 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $17 | $49,42931 claims |
| UCB, Inc.Neupro | $17 | $10,59711 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil | $22 | $3,00427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,996 neurology providers in California.
Other neurology in Upland
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
- Benjamin FrishbergCarlsbad$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.